Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.720
+0.020 (0.54%)
At close: Aug 13, 2025, 4:00 PM
3.850
+0.130 (3.49%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Larimar Therapeutics Employees
Larimar Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 23 or 54.76% compared to the previous year.
Employees
65
Change (1Y)
23
Growth (1Y)
54.76%
Revenue / Employee
n/a
Profits / Employee
-$1,465,092
Market Cap
318.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LRMR News
- 13 days ago - Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 15 days ago - Larimar Therapeutics Announces Pricing of Underwritten Public Offering - GlobeNewsWire
- 15 days ago - Larimar Therapeutics Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - GlobeNewsWire
- 7 weeks ago - Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program - GlobeNewsWire
- 7 weeks ago - Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - GlobeNewsWire
- 3 months ago - Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire